[go: up one dir, main page]

DE60120990D1 - Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen - Google Patents

Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen

Info

Publication number
DE60120990D1
DE60120990D1 DE60120990T DE60120990T DE60120990D1 DE 60120990 D1 DE60120990 D1 DE 60120990D1 DE 60120990 T DE60120990 T DE 60120990T DE 60120990 T DE60120990 T DE 60120990T DE 60120990 D1 DE60120990 D1 DE 60120990D1
Authority
DE
Germany
Prior art keywords
bezoylphenylacetic
treatment
acid derivatives
diseases
network
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60120990T
Other languages
English (en)
Other versions
DE60120990T2 (de
Inventor
A Gamache
Gustav Graff
M Yanni
A Kapin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Application granted granted Critical
Publication of DE60120990D1 publication Critical patent/DE60120990D1/de
Publication of DE60120990T2 publication Critical patent/DE60120990T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60120990T 2000-08-14 2001-08-13 Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen Expired - Lifetime DE60120990T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22513200P 2000-08-14 2000-08-14
US225132P 2000-08-14
PCT/US2001/025319 WO2002013805A2 (en) 2000-08-14 2001-08-13 Method of treating neurodegenerative disorders of the retina and optic nerve head

Publications (2)

Publication Number Publication Date
DE60120990D1 true DE60120990D1 (de) 2006-08-03
DE60120990T2 DE60120990T2 (de) 2007-03-15

Family

ID=22843666

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60120990T Expired - Lifetime DE60120990T2 (de) 2000-08-14 2001-08-13 Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen

Country Status (16)

Country Link
US (1) US6638976B2 (de)
EP (1) EP1309322B1 (de)
JP (1) JP2004506010A (de)
AR (1) AR030346A1 (de)
AT (1) ATE330596T1 (de)
AU (1) AU8125801A (de)
BR (1) BR0113201A (de)
CA (1) CA2418059C (de)
CY (1) CY1106155T1 (de)
DE (1) DE60120990T2 (de)
DK (1) DK1309322T3 (de)
ES (1) ES2266229T3 (de)
MX (1) MXPA03001160A (de)
PT (1) PT1309322E (de)
TW (1) TWI286933B (de)
WO (1) WO2002013805A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132773A1 (en) * 2001-08-13 2004-07-08 Gamache Daniel A Method of treating neurodgenerative disorders of the retina and optic nerve head
KR20060019579A (ko) * 2003-06-13 2006-03-03 알콘, 인코퍼레이티드 병적 눈 혈관형성을 치료하기 위한 비-스테로이드성항-염증제 제제
US20050009910A1 (en) * 2003-07-10 2005-01-13 Allergan, Inc. Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
TWI358290B (en) * 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
BRPI0608774A2 (pt) * 2005-05-10 2010-01-26 Alcon Inc composição de suspensão oftálmica aquosa topicamente administrável e uso da mesma
WO2006121963A2 (en) * 2005-05-10 2006-11-16 Alcon, Inc. Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders
US9370444B2 (en) 2010-10-12 2016-06-21 Emmett T. Cunningham, JR. Subconjunctival conformer device and uses thereof
US8915877B2 (en) 2010-10-12 2014-12-23 Emmett T. Cunningham, JR. Glaucoma drainage device and uses thereof
RU2458656C1 (ru) * 2011-06-17 2012-08-20 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ лечения оперированного незакрывшегося макулярного отверстия
WO2014207769A1 (en) 2013-06-27 2014-12-31 Mylan Laboratories Ltd Process for the preparation of nepafenac

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1226344A (de) 1967-07-31 1971-03-24
SE400966B (sv) * 1975-08-13 1978-04-17 Robins Co Inc A H Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror
US4313949A (en) * 1979-09-26 1982-02-02 A. H. Robins Company, Inc. Method of producing an inhibitory effect on blood platelet aggregation
US4254146A (en) * 1979-10-18 1981-03-03 A. H. Robins Company, Inc. 3-Benzoyl-2-nitrophenylacetic acids, metal salts, amides and esters
IL61945A (en) 1980-02-19 1984-09-30 Robins Co Inc A H 2-amino-3-(hydroxy(phenyl)methyl)phenylacetic acids,esters and amides and pharmaceutical compositions containing them
DE3026402A1 (de) * 1980-07-11 1982-02-04 Syntex Corp., Palo Alto, Calif. Die verwendung analgetischer und nicht-hormonaler, entzuendungshemmender mittel bei der behandlung von mikrovaskulaeren erkrankungen
US4503073A (en) 1981-01-07 1985-03-05 A. H. Robins Company, Incorporated 2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids
IL64724A0 (en) * 1981-02-17 1982-03-31 Robins Co Inc A H 2-amino-3-(halobenzoyl)-methylphenylacetic acids and esters and salts thereof and pharmaceutical compositions containing them
US4454151A (en) 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
US4568695A (en) * 1983-12-07 1986-02-04 A. H. Robins Company, Incorporated 2-Amino-3-benzoyl-phenethylalcohols and intermediates therefor
DE3668450D1 (de) 1985-03-14 1990-03-01 Smithkline Dauelsberg 5-aminosalicylsaeurederivate von nicht-steroidalen entzuendungshemmenden sauren.
US4851443A (en) 1985-03-14 1989-07-25 Smith Kline Dauelsberg, Gmbh Carboxylic acid amides, compositions and medical use thereof
US4683242A (en) * 1985-10-28 1987-07-28 A. H. Robins Company, Incorporated Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters
DK406686D0 (da) 1986-08-26 1986-08-26 Hans Bundgaard Carboxylsyrederivater
US4910225A (en) 1988-01-27 1990-03-20 Senju Pharmaceutical Co., Ltd. Locally administrable therapeutic composition for inflammatory disease
US5314909A (en) 1993-03-17 1994-05-24 Merck & Co., Inc. Use of non-steroidal antiiflammatory agents in macular degeneration
JP3396953B2 (ja) 1994-05-10 2003-04-14 千寿製薬株式会社 網膜疾患予防・治療剤
US5475034A (en) * 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
US5643943A (en) * 1994-12-23 1997-07-01 Alcon Laboratories, Inc. Systemic administration of esters and amides of antioxidants which may be used as antioxidant prodrug therapy for oxidative and inflammatory pathogenesis
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US6025353A (en) 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
US6066671A (en) * 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
BR9917001A (pt) 1999-01-07 2001-11-13 Univ Vanderbilt Conversão de compostos de inibição de cox quenão são inibidores seletivos de cox-2 em derivadosque são inibidores seletivos de cox-2
US6413965B1 (en) 1999-06-30 2002-07-02 Pfizer Inc. Compositions and treatment for diabetic complications
US6555540B1 (en) 1999-06-30 2003-04-29 Pfizer Inc Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
US6426341B1 (en) 1999-06-30 2002-07-30 Pfizer Inc. Treatment for diabetic complications
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device

Also Published As

Publication number Publication date
CA2418059A1 (en) 2002-02-21
AU8125801A (en) 2002-02-25
WO2002013805A3 (en) 2002-05-30
DE60120990T2 (de) 2007-03-15
US20020049255A1 (en) 2002-04-25
ATE330596T1 (de) 2006-07-15
TWI286933B (en) 2007-09-21
EP1309322B1 (de) 2006-06-21
WO2002013805A2 (en) 2002-02-21
AR030346A1 (es) 2003-08-20
CA2418059C (en) 2009-12-22
US6638976B2 (en) 2003-10-28
DK1309322T3 (da) 2006-10-23
HK1057332A1 (en) 2004-04-02
ES2266229T3 (es) 2007-03-01
BR0113201A (pt) 2006-05-09
MXPA03001160A (es) 2004-08-02
JP2004506010A (ja) 2004-02-26
PT1309322E (pt) 2006-11-30
CY1106155T1 (el) 2011-06-08
EP1309322A2 (de) 2003-05-14

Similar Documents

Publication Publication Date Title
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE417602T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
DE60230425D1 (de) Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
ATE358669T1 (de) Pyrazolderivate zur behandlung von hiv
DE60031710D1 (de) Fettsäurederivat zur behandlung von externen sekretionsstörungen
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
ATE418552T1 (de) Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE60120990D1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60018200D1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
ATE230741T1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen
DE69924284D1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten
ATE330938T1 (de) Disulfid-derivate verwendbar zur behandlung von allergischen erkrankungen
DE50212649D1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression
DE60005685D1 (de) Oxazinocarbazole zur behandlung von cns-erkrankungen
ATE272619T1 (de) Anilin-disulfid-derivate zur behandlung allergischer erkrankungen
ATE307805T1 (de) Imidazolonderivate zur behandlung viraler krankheiten
ATE343387T1 (de) S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition